Connect Biopharma Shares Jump 25% on Positive Phase 2 COPD Data
Connect Biopharma shares jumped 25% after positive Phase 2 COPD data for rademikibart, putting biotech catalyst volatility in focus.
Kodiak Sciences Nearly Triples to $90: Can a $5.64 Billion Valuation Hold?
Kodiak Sciences’ jump from roughly $32 to $90 creates a sharp clash between biotech momentum and the company’s funding risks.
Eli Lilly Builds Q4 Momentum With Positive Ebglyss Phase 3b Results
Positive Ebglyss and retatrutide trial updates give Eli Lilly’s pipeline broader support heading into Q4.
Capricor Therapeutics Jumps 12.8% as Analysts Raise Stakes Ahead of FDA Decision
CAPR traded 12.84% higher after B. Riley upgraded the stock to Buy, sharpening focus on deramiocel and its upcoming FDA decision.
AstraZeneca’s US Lung Cancer Filing Puts Its HUTCHMED Partnership in Focus
AstraZeneca’s FDA application for a HUTCHMED-linked lung cancer treatment marks a pipeline milestone, but it is not yet an approval.
Lantheus Stock May Be 14% Undervalued After BRAVNETSA FDA Approval
Lantheus’ BRAVNETSA approval may support a 14% fair-value gap, but SPARROW timing and capital needs remain key variables.
AbbVie’s Parkinson’s Drug Approval Fails to Lift Shares as ABBV Slips Nearly 1%
AbbVie won FDA approval for Juvmo, yet ABBV slipped nearly 0.8% as investors weighed expectations, market weakness and execution risks.
Egetis Shares Jump 13.2% After FDA Approves First MCT8 Deficiency Treatment
Egetis shares rose 13.2% after FDA approval of EMCITATE, putting rare-disease strategy and U.S. commercial questions in focus.
FDA Expands Eli Lilly’s Olumiant Label to Adolescents With Severe Alopecia
The FDA approved Eli Lilly’s once-daily Olumiant for adolescents with severe alopecia areata, expanding the commercial reach of an existing …
AbbVie’s Reported $10.9 Billion Apogee Deal Puts Pharma M&A and Pipeline Risk in Focus
AbbVie’s reported $10.9 billion Apogee deal highlights pipeline strategy, capital allocation and potential volatility for APGE and ABBV.
MediciNova Stock Falls 14.7% After Mixed Phase 2 NAFLD Results
MediciNova shares fell 14.7% in premarket trading after mixed Phase 2 results for tipelukast highlighted the binary risk of biotech readouts…
AbbVie Wins FDA Approval for Juvmo, but Medicare Timing Could Slow the Parkinson’s Drug Launch
AbbVie’s Juvmo won FDA approval, but missing Medicare’s 2027 window could make the drug’s U.S. launch slower than the regulatory win suggest…